Soleno Therapeutics (SLNO) Work In Process (2025 - 2026)
Soleno Therapeutics (SLNO) reported Work In Process of $5.6 million for Q1 2026, up 105.39% on a QoQ basis from $2.7 million in Q4 2025.
Soleno Therapeutics (SLNO) has 2 years of Work In Process data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Work In Process changed N/A year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (changed N/A YoY) and the FY2025 annual result came in at $2.7 million, changed N/A from the prior year.
- Work In Process grew to $5.6 million in Q1 2026 per SLNO's latest filing, from $2.7 million in the prior quarter.
- Across five years, Work In Process topped out at $5.6 million in Q1 2026 and bottomed at $950000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 950,000.00 |